Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Depomed Fails to Win U.S. Approval for Menopause Drug

Depomed Inc. failed to win U.S. approval for a drug to ease hot flashes associated with menopause that regulatory advisers had said was too risky to clear for sale.

The Food and Drug Administration can’t approve the application in its present form, the Newark, California-based company said in a statement today. Depomed, which already sells gabapentin as a treatment called Gralise for pain associated with shingles, reiterated that it won’t further invest in plans to expand the drug to be used for menopausal hot flashes.

The drug would have been a non-hormonal alternative to existing medicines found to increase the risk of heart attack, breast cancer and stroke. However, advisers to the FDA voted March 4 that the risks of gabapentin outweighed the benefits. The panel reached the same conclusion about another treatment to ease hot flashes from Hisamitsu Pharmaceutical Co.

Depomed said then it would stop spending on the drug’s development as a hot flash treatment.

Clinical trials struggled to show gabapentin had an effect up to 12 and 24 weeks out, FDA staff said in a February staff report. The treatment also carries a risk of suicidal thoughts as indicated on the labels of other drugs with the same active ingredient including Gralise and anti-seizure medications.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.